Solid tumor/s, Advanced malignancies, Cancer
ORICORIC PharmaceuticalsCatalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for Enozertinib (ORIC-114) in Solid tumor/s, Advanced malignancies, Cancer. The expected timing is based on the latest available company guidance and may change.
8/10/23- Present initial data at ESMO. 10/21/23- Initial Ph1 dose escalation data. 4/16/24 First patient dosed in all 3 expansion cohorts w/ NSCLC. 10/23/24 Poster presentation at EORTC-NCI-AACR 2024. 1/13/25- To initiate subq amivantamab cohort in Q1 '25, data in H2 2025 and in mid-2026. 11/13/25:- ESMO Asia 2025 data in December 2025 for multiple NSCLC EGFR/HER2 mutant cohorts. 12/05/25:- Reported ESMO Asia 2025 Ph1b NSCLC exon 20 data; next update expected Mid-2026. 01/12/26:- ESMO Asia Ph1b NSCLC showed strong systemic/CNS activity; 2H 2026 1L EGFR exon20/PACC monotherapy data planned. 02/23/26:- Reiterated plan for 2H 2026 1L EGFR exon20 and PACC monotherapy and SC amivantamab combo data. 05/04/26:- Completed 1L EGFR exon20 monotherapy Ph1b enrollment; 2H 2026 1L EGFR atypical, exon20 and SC amivantamab data expected. 07/20/26:- ESMO 2026 poster with Ph1b 1L EGFR atypical NSCLC data on Oct 26; abstracts Oct 19. 08/03/26:- ESMO atypical data due October 2026; exon20 and SC combo data due H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.